immunization to all people, regardless of where they are born, who they are, or where they live.
The GVAP sets out strategic objectives, recommends actions and stakeholder responsibilities for achieving the objectives, and provides for monitoring and evaluation of the plan’s implementation. All WHA countries now report annually on progress against GVAP indicators.
The plan was the result of a global collaboration involving governments and elected officials, health professionals, academic institutions, vaccine manufacturers, nongovernmental organizations, and civil society organizations.
If the global community meets the plan’s objectives, childhood mortality around the world will be reduced below the targets set by the United Nations Millennium Development Goals.
Global immunization coverage has never been higher. More than 100 million children are immunized each year against tuberculosis, polio, measles, diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type B, and, in some countries, yellow fever. These vaccines save an estimated 2.5 million lives each year.
Nearly 200 countries around the globe have endorsed a shared vision—known as the Decade of Vaccines—to extend the benefits of vaccines to every person by 2020 and thereby save more than 20 million lives. This international collaboration has generated the Global Vaccine Action Plan (GVAP), a framework for preventing millions of deaths by 2020 through more equitable access to existing vaccines for people in all communities.
At A Glance
About 1.5 million children die each year from vaccine-preventable diseases.
More than 70 percent of the world’s unvaccinated children live in 10 countries with large populations and weak immunization systems.
The foundation works to ensure that existing life-saving vaccines are delivered where they are needed most. We also support development of new vaccines and new delivery technologies and approaches.
We have committed US$2.5 billion to the GAVI Alliance, a global public-private partnership that has been instrumental in expanding access to existing vaccines and speeding the introduction of new vaccines in developing countries.
Our Vaccine Delivery team is led by Orin Levine, director, and is part of the foundation’s Global Development Division.
Vaccines save millions of lives each year and are among the most cost-effective health interventions ever developed. Immunization has led to the eradication of smallpox, a 74 percent reduction in childhood deaths from measles over the past decade, and the near-eradication of polio.
Despite these great strides, there remains an urgent need to reach all children with life-saving vaccines. One in five children worldwide are not fully protected with even the most basic vaccines. As a result, an estimated 1.5 million children die each year—one every 20 seconds—from vaccine-preventable diseases such as diarrhea and pneumonia. Tens of thousands of other children suffer from severe or permanently disabling illnesses.
Vaccines are often expensive for the world’s poorest countries, and supply shortages and a lack of trained health workers are challenges as well. Unreliable transportation systems and storage facilities also make it difficult to preserve high-quality vaccines that require refrigeration.
and I have no problem with that, since they don't. I won't be sorry in the long run, but I guarantee you will.
Well here is what another poster responded to me: So why did this happen if 2 or 3 three years out affects the present?
oncsinvestor • 45 minutes ago
gigo, you ask the wrong question. The question should be: 'Once INO's platform has been validated HOW MANY drugs do you see on the market?' It does not really matter when that will be (1, 2, or 3 years), because you know it's coming once we have the final validation through a commercial drug. In... More
Sentiment: Strong Buy
Sure and you all missed this at the time. Right?
Inovio Pharmaceuticals Announces Reverse Stock Split Date
BLUE BELL, Pa., May 30, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that its previously announced 1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company's common stock on a post-reverse split basis shall commence on Friday, June 6, 2014. The common stock will continue to trade under the symbol "INO."
As filed on May 22, 2014, the Company's stockholders approved the proposal of a reverse split of the Company's common stock. The Company's Board of Directors subsequently approved the immediate implementation of a 1-for-4 reverse stock split of the Company's common stock, where each 4 shares of issued and outstanding common stock and equivalents will be converted into 1 share of common stock.
agree it would be of validation. So when do you see the first profitable drug on the market from INO? 3,5 or more years away? and why?
So where do you value a reward for the first zika vaccine to market?
What does that make all you calling for extreme valuations?
Yes and the real Santa Claus is sitting in my living room with me. He says Hi.
The share value will drop like rock. That's what is known as PUMP and DUMP. Investors should be very cautious and wait for a much more value oriented entry point.
Exactly what I mean. Traders using speculation to hype value. Not investors. Be careful.
Using the disease fear factor to PUMP you speculation, is desperation. Not reality. My statements are reality. Stop your BS.
Yes just keep buying LOL
and the enthusiasm you folks display is the same. See where they are now.
rather than realistic chances, financials and ability to produce real returns. Potential is always an early incentive but that's all there is now and it is certainly far from guaranteed as many of you seem to imply.